NCT05242484: A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
- State
- Under way
- Phase
- Phase 2
- People
- 577 taking part
- Started
- 19 Sep 2022
- Primary completion
- 15 May 2025
- Arms
- Group 4: JNJ-78934804 (High-dose), Group 5: JNJ-78934804 (Mid-dose), Group 6: JNJ-78934804 (Low-dose)
- Results
- None posted
- 16 Feb 2022: Trial registered
- 19 Sep 2022: Trial started